600 mg once daily bexobrutideg oral dose cleared by global regulators for pivotal monotherapy trials in relapsed/refractory chronic lymphocytic leukemia (r/r CLL) Phase 2 DAYBreak trial initiated for potential Accelerated Approval New preclinical data support bexobrutideg as potential best-in-class BTK degrader profile Nurix will host an investor webcast today, Wednesday, October 22nd, at 8:00 a.m. EDT SAN FRANCISCO, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage ...

Core Insights - NX-1607 is a first-in-class oral inhibitor of CBL-B, demonstrating on-target peripheral immune activation and anti-tumor activity in heavily pretreated patients with advanced solid tumors [1][2][4] - The clinical data presented at ESMO 2025 supports the initiation of expansion cohorts for further evaluation of NX-1607 as a monotherapy or in combination therapies [1][2] Company Overview - Nurix Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on targeted protein degradation medicines, aiming to improve treatment options for cancer and inflammatory diseases [7] - The company is advancing multiple clinical and preclinical programs, including NX-1607 and bexobrutideg, an oral BTK degrader [7] Clinical Data Summary - In a Phase 1a study, 82 patients with various solid tumors were treated with NX-1607 across different dosing regimens, showing a disease control rate (DCR) of 49.3% [2][3] - Notable clinical activity included reductions in tumor-specific biomarkers, long-term stable disease, and a confirmed partial response in a patient with micro-satellite stable colorectal cancer [2][3] - The most significant reductions in prostate-specific antigen (PSA) were observed in patients receiving BID dosing, with 6 out of 13 patients achieving PSA reductions of ≥50% [2] Safety Profile - NX-1607 exhibited a tolerable safety profile, comparable to approved immuno-oncology agents, with most adverse events being Grade 2 or less [3] - Immune-related adverse events were observed in 6 patients, indicating on-target immune activation similar to PD-1/PD-L1 therapies [3] Future Development - The company plans to further explore the therapeutic potential of NX-1607, particularly in indications where current immunotherapies have shown limited efficacy, such as MSS colorectal cancer and metastatic prostate cancer [4]

Core Insights - NX-1607 is a first-in-class oral inhibitor of CBL-B, demonstrating on-target peripheral immune activation and anti-tumor activity in heavily pretreated patients with advanced solid tumors [1][2][4] - The clinical data presented at ESMO 2025 supports the initiation of expansion cohorts for further evaluation of NX-1607 as a monotherapy or in combination therapies [1][2] Company Overview - Nurix Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on targeted protein degradation medicines, aiming to improve treatment options for cancer and inflammatory diseases [7] - The company is advancing multiple clinical and preclinical programs, including NX-1607 and bexobrutideg, an oral BTK degrader [7] Clinical Data Summary - In a Phase 1a study, 82 patients with various solid tumors were treated with NX-1607 across different dosing regimens, showing dose-dependent exposure and clinical activity [2][3] - The disease control rate (DCR) was reported at 49.3%, with notable reductions in tumor-specific biomarkers such as PSA and CEA [2][3] - The treatment was well-tolerated, with most adverse events being Grade 2 or less, and immune-related adverse events indicating on-target immune activation [3][4] Therapeutic Potential - NX-1607 targets a previously unaddressed pathway in immune regulation, affecting multiple immune cell types, which may enhance its efficacy in treating solid tumors [2][6] - The results are particularly promising for tumor types like micro-satellite stable colorectal cancer and metastatic prostate cancer, where current immunotherapies have shown limited efficacy [4]

Core Insights - Nurix Therapeutics is focused on developing innovative therapies for cancer treatment, particularly its oral BTK degrader, bexobrutideg, targeting chronic lymphocytic leukemia (CLL) [1][5] - The company plans to initiate a pivotal phase 2 study in late 2025, indicating a strong commitment to advancing its clinical programs [1][5] Financial Summary - Stifel Nicolaus has set a price target of $33 for NRIX, suggesting a potential upside of approximately 238% from its current price of $9.76 [2][5] - The stock has experienced a decrease of 10.13%, reflecting market volatility, while the company's market capitalization stands at $750.3 million [2] Clinical Data - Nurix's phase 1a data for bexobrutideg shows an impressive 80.9% overall response rate (ORR), supporting the potential for Accelerated Approval [3][5] - The company aims to expand its efforts with a phase 3 trial and explore combination therapies for CLL, targeting a multibillion-dollar market [3][5] Stock Performance - The stock has fluctuated between $9.50 and $10.56 today, with a 52-week high of $29.56 and a low of $8.18, indicating active investor interest [4] - Trading volume stands at 1,996,408 shares, suggesting significant market activity [4]

Core Insights - Nurix Therapeutics is advancing its clinical development plans for bexobrutideg, targeting relapsed/refractory chronic lymphocytic leukemia (CLL) with pivotal trials set to begin in the second half of 2025 [1][2] - The company reported a cash position of $428.8 million as of August 31, 2025, indicating strong capitalization for ongoing and future projects [1][8] Clinical Development - Bexobrutideg is set to undergo a single-arm study for potential accelerated approval in relapsed/refractory CLL patients, alongside a randomized controlled Phase 3 trial [2] - Preclinical data for GS-6791, an IRAK4 degrader developed in collaboration with Gilead, demonstrated significant efficacy in a dermatitis model, showcasing its potential in autoimmune diseases [1][2] - Recent Phase 1a data for bexobrutideg in CLL showed an overall response rate (ORR) of 80.9% among 47 evaluable patients, with rapid responses and durable activity noted [2][3] Financial Performance - Revenue for the fiscal quarter ended August 31, 2025, was $7.9 million, a decrease from $12.6 million in the same quarter of 2024, primarily due to the conclusion of the initial research term with Sanofi [4] - Research and development expenses increased to $86.1 million from $55.5 million year-over-year, reflecting accelerated clinical activities [5] - The net loss for the quarter was $86.4 million, or $1.03 per share, compared to a net loss of $49.0 million, or $0.67 per share, in the prior year [6] Pipeline and Collaborations - Nurix is also advancing other drug candidates, including Zelebrudomide for B-cell malignancies and NX-1607 for immuno-oncology indications, with ongoing clinical trials [7] - The company maintains strategic collaborations with Gilead, Sanofi, and Pfizer, focusing on various degrader programs and anticipating further updates throughout 2025 [7]

Core Insights - Nurix Therapeutics is advancing its Phase III trial for bexobrutideg, a targeted protein degrader, which represents a new class of therapeutics in the industry [2][3][4] - The company positions bexobrutideg as the first drug in its category, indicating a significant evolution in therapeutic approaches beyond traditional small molecule inhibitors and antibodies [3][4] Company Overview - Arthur Sands serves as the President and CEO of Nurix Therapeutics, leading the discussion on the company's innovative drug development [1] - The company emphasizes the importance of targeted protein degraders in the context of evolving therapeutic modalities, suggesting a strategic focus on this new mechanism of action (MOA) [3][4] Industry Context - The presentation highlights the transition from traditional therapies, such as small molecule inhibitors and DNA-based therapeutics, to a new class of drugs represented by targeted protein degraders [3][4] - The introduction of bexobrutideg is seen as a potential game-changer in the therapeutic landscape, indicating a shift in how diseases may be treated in the future [4]

Core Insights - Nurix Therapeutics is advancing its Phase III trial design for its lead program, bexobrutideg, which represents a new class of therapeutics known as targeted protein degraders [2][3][4] - The company positions bexobrutideg as the first drug in this new mechanism of action (MOA), indicating its potential significance in the evolution of therapeutic options [3][4] Company Overview - Arthur Sands serves as the President and CEO of Nurix Therapeutics, leading the discussion on the company's innovative approaches [1][3] - The company emphasizes the transition from traditional therapies, such as small molecule inhibitors and antibodies, to a novel class of drugs that utilize targeted protein degradation [3][4]

Core Insights - Nurix Therapeutics presented multiple preclinical data at the AACR 2025 Annual Meeting, showcasing advancements in targeted protein degradation therapies for cancer treatment [1][2][3] Group 1: Bexobrutideg (NX-5948) - Bexobrutideg, a BTK degrader, can degrade approximately 10,000 copies of BTK per hour, demonstrating high catalytic efficiency [2] - It shows CNS exposure and is detectable in cerebrospinal fluid, indicating potential effectiveness in treating CNS-related cancers [2][6] Group 2: NRX-0305 - NRX-0305 is a pan-mutant BRAF degrader that effectively targets all three classes of BRAF mutations while sparing healthy cells [3][7] - Preclinical data indicate that NRX-0305 has broad anti-tumor efficacy, particularly in tumors resistant to existing therapies [3][7] Group 3: Aurora A Kinase Degraders - Nurix is developing selective, orally bioavailable degraders of Aurora A kinase (AURKA) for treating aggressive childhood cancers [4][5] - Preclinical studies of NRX-4972, an AURKA degrader, show significant efficacy in neuroblastoma models, outperforming traditional AURKA inhibitors [5][8] Group 4: Company Overview - Nurix Therapeutics focuses on the discovery and development of targeted protein degradation medicines, aiming to improve treatment options for cancer and inflammatory diseases [9] - The company utilizes an AI-integrated discovery engine and has collaborations with major pharmaceutical companies for drug development [9]